EP Patent

EP2094275A2 — Methods and formulations for improved bioavailability of antiprogestins

Assigned to Repros Therapeutics Inc · Expires 2009-09-02 · 17y expired

What this patent protects

Compositions comprising an antiprogestin and having improved bioavailability are provided. In one aspect, compositions comprising particles of an antiprogestin deposited on a carrier substrate are provided. In another aspect, compositions comprising a micronized antiprogestin are…

USPTO Abstract

Compositions comprising an antiprogestin and having improved bioavailability are provided. In one aspect, compositions comprising particles of an antiprogestin deposited on a carrier substrate are provided. In another aspect, compositions comprising a micronized antiprogestin are provided. Also provided is the use of compositions comprising an antiprogestin and having improved bioavailability for the treatment of endometriosis, uterine fibroids, dysmenorrhea, and meningiomas.

Drugs covered by this patent

Patent Metadata

Patent number
EP2094275A2
Jurisdiction
EP
Classification
Expires
2009-09-02
Drug substance claim
No
Drug product claim
No
Assignee
Repros Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.